BAY 58-2667, an NO-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts

Documenti analoghi

• Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
  di: Ritchie, Rebecca, et al.
  Pubblicazione: (2009)
• The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
  di: Irvine, Jennifer C., et al.
  Pubblicazione: (2012)
• Structure of Cinaciguat (BAY 58–2667) Bound to Nostoc H-NOX Domain Reveals Insights into Heme-mimetic Activation of the Soluble Guanylyl Cyclase
  di: Martin, Faye, et al.
  Pubblicazione: (2010)
• Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
  di: Radovits, Tamás, et al.
  Pubblicazione: (2009)
• Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
  di: Frey, Reiner, et al.
  Pubblicazione: (2011)